gym, workplace, travel, and others), supporting and fostering a more consistent management and routine.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a group of oral hypoglycemic agents used to manage Type 2 Diabetes Mellitus, which is a significant risk factor for coronary disease, heart failure, stroke, and many other cardiovascular conditions

These include anorectic effects driven by previously discussed central modulation of satiety and reward pathways and peripheral activation of vagal afferents, delayed gastric emptying, anti-inflammatory properties, potential impact on energy expenditure and the ability to reduce ghrelin levels, which are inherently elevated in PWS ( 2 to 11.3 kg/m 2 ( 2 in 10/14 cases, and an HbA1c improvement in 19/23 cases, without reported serious side effects ( Semaglutide at a dose of 2.4 mg weekly is the first weekly long-acting GLP-1 RA approved for non-syndromic obesity treatment with a mean weight change of 14.9% in individuals with obesity without diabetes ( Our case series presents the long-term efficacy and safety of semaglutide treatment in patients with PWS without diabetes as well as semaglutide efficacy and safety in PWS previously treated with metabolic surgery

The SUSTAIN clinical trial program, encompassing multiple Phase III studies with thousands of patients, generated definitive efficacy and safety data
But the real story will come from the pivotal trials starting this year
Advantages of Oral Supplements: Convenience represents oral supplementations primary benefit